TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (ASCEND Trial)
Brief Summary: PIPF-016 (ASCEND) is a Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. The study objectives are to confirm the treatment effect of pirfenidone compared with placebo on change in percent predicted forced vital capacity (%FVC) in patients with idiopathic pulmonary fibrosis (IPF), and to confirm the safety of treatment with pirfenidone compared with placebo in patients with IPF.


Options:
A: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: BIBF 1120; Type: EXPERIMENTAL; Interventions: Drug: BIBF 1120 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: BIBF 1120; Assigned to Arm(s): BIBF 1120
B: Arm Label: Active Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pirfenidone | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pirfenidone; Assigned to Arm(s): Active Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Arm
C: Arm Label: Pulmonary rehabilitation; Type: EXPERIMENTAL; Interventions: Other: Pulmonary rehabilitation program | Arm Label: Controls; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Pulmonary rehabilitation program; Assigned to Arm(s): Pulmonary rehabilitation
D: Arm Label: BIBF 1120; Type: EXPERIMENTAL; Interventions: Drug: BIBF 1120 | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: BIBF 1120; Assigned to Arm(s): BIBF 1120

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (ASCEND Trial)
Brief Summary: PIPF-016 (ASCEND) is a Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. The study objectives are to confirm the treatment effect of pirfenidone compared with placebo on change in percent predicted forced vital capacity (%FVC) in patients with idiopathic pulmonary fibrosis (IPF), and to confirm the safety of treatment with pirfenidone compared with placebo in patients with IPF.


Options:
A: Arm Label: Mycophenolate Arm; Type: EXPERIMENTAL; Interventions: Drug: Mycophenolate mofetil | Arm Label: Cyclophosphamide Arm; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide, Drug: Placebo | Intervention Type: DRUG; Name: Mycophenolate mofetil; Assigned to Arm(s): Mycophenolate Arm | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Cyclophosphamide Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cyclophosphamide Arm
B: Arm Label: 2403 mg/day pirfenidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pirfenidone | Arm Label: 1197 mg/day pirfenidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pirfenidone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pirfenidone; Assigned to Arm(s): 1197 mg/day pirfenidone, 2403 mg/day pirfenidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: Active Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pirfenidone | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pirfenidone; Assigned to Arm(s): Active Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Arm
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: N-acetylcysteine (NAC) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: N-acetylcysteine (NAC); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Median Effective Dose (ED50) of Paracetamol and Morphine for Postoperative Patients: A Study of Interaction.
Brief Summary: The aim of our study is to define the median effective analgesic doses (ED50) of paracetamol, morphine, and their combination and determination the nature of their interaction administered IV for postoperative pain after moderate painful surgery using up-and-down and isobolographic methods.


Options:
A: Arm Label: IV Placebo 100 ml; Type: PLACEBO_COMPARATOR; Interventions: Drug: IV Placebo | Arm Label: IV Placebo 65 ml; Type: PLACEBO_COMPARATOR; Interventions: Drug: IV Placebo | Arm Label: IV Acetaminophen 1 gm; Type: EXPERIMENTAL; Interventions: Drug: IV Acetaminophen | Arm Label: IV Acetaminophen 650 mg; Type: EXPERIMENTAL; Interventions: Drug: IV Acetaminophen | Intervention Type: DRUG; Name: IV Placebo; Assigned to Arm(s): IV Placebo 100 ml | Intervention Type: DRUG; Name: IV Placebo; Assigned to Arm(s): IV Placebo 65 ml | Intervention Type: DRUG; Name: IV Acetaminophen; Assigned to Arm(s): IV Acetaminophen 1 gm | Intervention Type: DRUG; Name: IV Acetaminophen; Assigned to Arm(s): IV Acetaminophen 650 mg
B: Arm Label: Paracetamol; Type: EXPERIMENTAL; Interventions: Drug: Paracetamol | Arm Label: Morphine; Type: EXPERIMENTAL; Interventions: Drug: Morphine | Arm Label: Paracetamol-morphine; Type: EXPERIMENTAL; Interventions: Drug: Paracetamol- Morphine | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Paracetamol | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Morphine | Intervention Type: DRUG; Name: Paracetamol- Morphine; Assigned to Arm(s): Paracetamol-morphine
C: Arm Label: Lornoxicam; Type: EXPERIMENTAL; Interventions: Drug: Lornoxicam | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Paracetamol; Type: EXPERIMENTAL; Interventions: Drug: Paracetamol | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Paracetamol | Intervention Type: DRUG; Name: Lornoxicam; Assigned to Arm(s): Lornoxicam
D: Arm Label: Paracetamol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paracetamol | Arm Label: Dipyrone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dipyrone | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Paracetamol | Intervention Type: DRUG; Name: Dipyrone; Assigned to Arm(s): Dipyrone

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Directional AthErectomy Followed by a PaclItaxel-Coated BallooN to InhibiT RestenosIs and Maintain Vessel PatEncy: A Pilot Study of Anti-Restenosis Treatment
Brief Summary: The DEFINITIVE AR study is a prospective, multi-center, randomized pilot study evaluating the use of either the TurboHawk™ or SilverHawk® plaque excision systems followed by treatment with the Cotavance™ drug-eluting balloon catheter versus the Cotavance balloon catheter alone in patients with peripheral arterial disease.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Percutaneous Transluminal Angioplasty | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Device: LifeStent NT™ Self-Expanding Peripheral Stent | Intervention Type: OTHER; Name: Percutaneous Transluminal Angioplasty; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: LifeStent NT™ Self-Expanding Peripheral Stent; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: PTA with placement of paclitaxel-eluting stent | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: PTA | Intervention Type: DEVICE; Name: PTA with placement of paclitaxel-eluting stent; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: PTA; Assigned to Arm(s): 2
C: Arm Label: Drug-eluting balloon; Type: EXPERIMENTAL; Interventions: Device: Cotavance Drug-Eluting Balloon | Arm Label: Plaque excision + drug-eluting balloon; Type: EXPERIMENTAL; Interventions: Device: TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon | Arm Label: Severely Ca++ Group; Type: EXPERIMENTAL; Interventions: Device: TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon | Intervention Type: DEVICE; Name: Cotavance Drug-Eluting Balloon; Assigned to Arm(s): Drug-eluting balloon | Intervention Type: DEVICE; Name: TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon; Assigned to Arm(s): Plaque excision + drug-eluting balloon | Intervention Type: DEVICE; Name: TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon; Assigned to Arm(s): Severely Ca++ Group
D: Arm Label: Rotational Atherectomy + PES; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Rotational Atherectomy + PES | Arm Label: Standard Treatment (PES without Rotational Atherectomy); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard Treatment (PES without Rotational Atherectomy) | Intervention Type: PROCEDURE; Name: Rotational Atherectomy + PES; Assigned to Arm(s): Rotational Atherectomy + PES | Intervention Type: PROCEDURE; Name: Standard Treatment (PES without Rotational Atherectomy); Assigned to Arm(s): Standard Treatment (PES without Rotational Atherectomy)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Renal Denervation on Blood Pressure and Clinical Course of Obstructive Sleep Apnea in Patients With Resistant Hypertension
Brief Summary: The purpose of this study is to investigate the clinical utility of renal denervation for the treatment of resistant hypertension coexisting with obstructive sleep apnea.


Options:
A: Arm Label: Renal Denervation; Type: EXPERIMENTAL; Interventions: Device: Symplicity Spyral™ multi-electrode renal denervation system | Arm Label: Sham Procedure; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham Procedure | Intervention Type: DEVICE; Name: Symplicity Spyral™ multi-electrode renal denervation system; Assigned to Arm(s): Renal Denervation | Intervention Type: PROCEDURE; Name: Sham Procedure; Assigned to Arm(s): Sham Procedure
B: Arm Label: Renal Denervation plus Medications; Type: EXPERIMENTAL; Interventions: Device: Radiofrequency ablation catheter, Drug: Amlodipine, losartan potassium and hydrochlorothiazide | Arm Label: Medications; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amlodipine, losartan potassium and hydrochlorothiazide | Intervention Type: DEVICE; Name: Radiofrequency ablation catheter; Assigned to Arm(s): Renal Denervation plus Medications | Intervention Type: DRUG; Name: Amlodipine, losartan potassium and hydrochlorothiazide; Assigned to Arm(s): Medications, Renal Denervation plus Medications
C: Arm Label: Renal Denervation; Type: EXPERIMENTAL; Interventions: Device: Renal denervation with a catheter-based procedure (Symplicity® Catheter System) | Arm Label: Maintenance of Medications; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Renal denervation with a catheter-based procedure (Symplicity® Catheter System); Assigned to Arm(s): Renal Denervation
D: Arm Label: Ultrasound Renal Denervation; Type: EXPERIMENTAL; Interventions: Device: The Paradise® Renal Denervation Ultrasound System | Arm Label: Sham Procedure; Type: SHAM_COMPARATOR; Interventions: Device: Sham Procedure | Intervention Type: DEVICE; Name: The Paradise® Renal Denervation Ultrasound System; Assigned to Arm(s): Ultrasound Renal Denervation | Intervention Type: DEVICE; Name: Sham Procedure; Assigned to Arm(s): Sham Procedure

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Development of a Yoga Intervention for Symptoms Related to Severe Visual Impairment
Brief Summary: This study aims to provide novel information on the feasibility of yoga interventions for secondary symptoms related to severe vision loss, such as sleep disturbances, negative mood states, fall risk and balance. This information will be important for determining safe, cost-effective and reliable practices for the benefits of yoga as an alternative means for improved health and well-being. A yoga intervention that is integrative and evidence-based will benefit the blind population through effective treatments and prevention of secondary symptoms as well as serve to inform rehabilitation specialists, educators, and clinicians in the future.


Options:
A: Arm Label: BA-LVR; Type: EXPERIMENTAL; Interventions: Behavioral: BA-LVR | Arm Label: ST-LVR; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: ST-LVR | Intervention Type: BEHAVIORAL; Name: BA-LVR; Assigned to Arm(s): BA-LVR | Intervention Type: BEHAVIORAL; Name: ST-LVR; Assigned to Arm(s): ST-LVR
B: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Arm Label: Overground visual cue training; Type: EXPERIMENTAL; Interventions: Behavioral: Overground visual cue training | Arm Label: Treadmill visual cue training; Type: EXPERIMENTAL; Interventions: Behavioral: Treadmill visual cue training | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual Care | Intervention Type: BEHAVIORAL; Name: Overground visual cue training; Assigned to Arm(s): Overground visual cue training | Intervention Type: BEHAVIORAL; Name: Treadmill visual cue training; Assigned to Arm(s): Treadmill visual cue training
C: Arm Label: Yoga Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Yoga Intervention | Intervention Type: BEHAVIORAL; Name: Yoga Intervention; Assigned to Arm(s): Yoga Therapy
D: Arm Label: regular O&M-training; Type: ACTIVE_COMPARATOR; Interventions: Other: orientation and mobility training | Arm Label: standardised O&M-training; Type: EXPERIMENTAL; Interventions: Other: orientation and mobility training | Intervention Type: OTHER; Name: orientation and mobility training; Assigned to Arm(s): regular O&M-training, standardised O&M-training

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects on Cytokines, Immunoglobulins, Antibodies, Sphingomyelinase and PAF Hydrolysis Capacity in the Maternal Milk After Probiotic VSL#3 Administration in the Last Four Weeks of Gestation and First Month of Lactation
Brief Summary: The newborn immune system is influenced by maternal immunity through both placenta and breastfeeding.

There exists a close interaction between the mother and the baby during gestation and lactation. Maternal milk contains a number of factors that protect the newborn against infections including 1) cytokines and their receptors which are also thought to play a role in the protection against allergies; 2) oligosaccharides with low molecular weight and 3) probiotic bacteria that contribute to the development of the newborn immune system.

Probiotics have a potent immunogenic activity as well as an immunoprotective potential in maternal milk after administration of probiotics during pregnancy and breastfeeding. In addition probiotics are supposed to play a role in the increased production of sphingomyelinase.


Options:
A: Intervention Type: DRUG; Name: Lactobacillus rhamnosus GR1 and Lactobacillus reuteri RC-14; Assigned to Arm(s): N/A
B: Arm Label: Vivomixx®; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vivomixx® | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vivomixx®; Assigned to Arm(s): Vivomixx® | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Probiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotics | Arm Label: Probiotics + Dietary counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and probiotics | Arm Label: Dietary counseling + placebo; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and placebo | Arm Label: Prebiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Prebiotics | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo capsules | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary counselling and placebo; Assigned to Arm(s): Dietary counseling + placebo | Intervention Type: BEHAVIORAL; Name: Dietary counselling and probiotics; Assigned to Arm(s): Probiotics + Dietary counseling | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo capsules; Assigned to Arm(s): Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotics; Assigned to Arm(s): Probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Prebiotics; Assigned to Arm(s): Prebiotics
D: Arm Label: VSL#3 probiotic preparation; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: VSL#3 probiotic preparation | Arm Label: Placebo VSL#3; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo VSL#3 | Intervention Type: DIETARY_SUPPLEMENT; Name: VSL#3 probiotic preparation; Assigned to Arm(s): VSL#3 probiotic preparation | Intervention Type: OTHER; Name: Placebo VSL#3; Assigned to Arm(s): Placebo VSL#3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Technology Enhanced Delivery of Treatment for Early Conduct Problems
Brief Summary: This study aimed to examine if technology could enhance the treatment engagement and outcomes of low income parents of 3 to 8 children with externalizing problems.


Options:
A: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Home visitation through pregnancy; Type: EXPERIMENTAL; Interventions: Behavioral: nurse home visitation | Arm Label: Home visitation through age 2; Type: EXPERIMENTAL; Interventions: Behavioral: nurse home visitation | Intervention Type: BEHAVIORAL; Name: nurse home visitation; Assigned to Arm(s): Home visitation through age 2, Home visitation through pregnancy
B: Arm Label: Usual Care control (Parenting tips); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Strongest Families; Type: EXPERIMENTAL; Interventions: Behavioral: Strongest Families | Intervention Type: BEHAVIORAL; Name: Strongest Families; Assigned to Arm(s): Strongest Families
C: Arm Label: Behavioral Parent Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral Parent Training | Arm Label: Behavioral Parent Training - Enhanced; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Parent Training | Intervention Type: BEHAVIORAL; Name: Behavioral Parent Training; Assigned to Arm(s): Behavioral Parent Training, Behavioral Parent Training - Enhanced
D: Arm Label: Helping the Noncompliant Child (HNC); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Helping the Noncompliant Child (HNC) | Arm Label: Technology-Enhanced HNC (TE-HNC); Type: EXPERIMENTAL; Interventions: Behavioral: Technology-Enhanced Helping the Noncompliant Child (TE-HNC) | Intervention Type: BEHAVIORAL; Name: Helping the Noncompliant Child (HNC); Assigned to Arm(s): Helping the Noncompliant Child (HNC) | Intervention Type: BEHAVIORAL; Name: Technology-Enhanced Helping the Noncompliant Child (TE-HNC); Assigned to Arm(s): Technology-Enhanced HNC (TE-HNC)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Hand in Hand. Psychological Intervention for Breast Cancer Patients and Their Partners. A Randomised, Controlled Trial.
Brief Summary: This study evaluates the effect of a psychological intervention to breast cancer patients and their partners compared to a control group receiving usual care


Options:
A: Arm Label: Brief; Type: EXPERIMENTAL; Interventions: Behavioral: Brief FOCUS Program | Arm Label: Extensive; Type: EXPERIMENTAL; Interventions: Behavioral: Extensive FOCUS Program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Brief FOCUS Program; Assigned to Arm(s): Brief | Intervention Type: BEHAVIORAL; Name: Extensive FOCUS Program; Assigned to Arm(s): Extensive
B: Arm Label: Psycho-educational support group therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Psycho-educational support group therapy | Intervention Type: BEHAVIORAL; Name: Psycho-educational support group therapy; Assigned to Arm(s): Psycho-educational support group therapy
C: Arm Label: Experimental: supportive care; Type: EXPERIMENTAL; Interventions: Other: Supportive care | Arm Label: Control: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Supportive care; Assigned to Arm(s): Experimental: supportive care
D: Arm Label: Psychological Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Psychological intervention | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Psychological intervention; Assigned to Arm(s): Psychological Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: MASTER: MGUARD for Acute ST Elevation Reperfusion
Brief Summary: The goal of this study is to demonstrate the superiority of the MGuard™ stent over commercially-approved bare-metal (BMS) /drug-eluting stents (DES) in achieving better myocardial reperfusion in primary angioplasty for the treatment of acute ST-elevation myocardial infarction (STEMI).


Options:
A: Arm Label: XIENCE V®; Type: EXPERIMENTAL; Interventions: Device: XIENCE V® Everolimus Eluting Coronary Stent | Arm Label: TAXUS™ EXPRESS2™; Type: ACTIVE_COMPARATOR; Interventions: Device: TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent | Intervention Type: DEVICE; Name: XIENCE V® Everolimus Eluting Coronary Stent; Assigned to Arm(s): XIENCE V® | Intervention Type: DEVICE; Name: TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent; Assigned to Arm(s): TAXUS™ EXPRESS2™
B: Intervention Type: PROCEDURE; Name: Primary angioplasty in acute myocardial infarction; Assigned to Arm(s): N/A
C: Arm Label: MGuard; Type: EXPERIMENTAL; Interventions: Device: MGuard | Arm Label: BMS or DES; Type: ACTIVE_COMPARATOR; Interventions: Device: Control BMS or DES | Intervention Type: DEVICE; Name: MGuard; Assigned to Arm(s): MGuard | Intervention Type: DEVICE; Name: Control BMS or DES; Assigned to Arm(s): BMS or DES
D: Arm Label: Drug Eluting Absorbable Metal Scaffold; Type: EXPERIMENTAL; Interventions: Device: Percutaneous Coronary Intervention (DREAMS) stenting | Intervention Type: DEVICE; Name: Percutaneous Coronary Intervention (DREAMS) stenting; Assigned to Arm(s): Drug Eluting Absorbable Metal Scaffold

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effective Analgesia Using the 5 S's During Routine Immunizations at 2 and 4 Months
Brief Summary: The purpose of this study is to observe and measure the analgesic effectiveness of the 5 S's (swaddling, side/stomach position, shushing, swinging, and sucking) alone and combined with sucrose, during routine immunizations at 2 and 4 month well child visits.


Options:
A: Arm Label: control; Type: N/A; Interventions: N/A | Arm Label: sucrose; Type: N/A; Interventions: N/A | Arm Label: physical intervention; Type: N/A; Interventions: N/A | Arm Label: physical intervention and sucrose; Type: N/A; Interventions: N/A
B: N/A
C: Arm Label: Co-bedding; Type: EXPERIMENTAL; Interventions: Procedure: Co-bedding (caring for twins in the same incubator) | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Co-bedding (caring for twins in the same incubator); Assigned to Arm(s): Co-bedding
D: Arm Label: OH; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Hernia repair | Arm Label: LH; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Hernia repair | Intervention Type: PROCEDURE; Name: Hernia repair; Assigned to Arm(s): LH, OH

Answer: A